Skip to main content

Master of Public Health

Number-needed-to-treat analysis of clinical progression in patients with metastatic castration-resistant prostate cancer in the STRIVE and TERRAIN trials.

AUTHORS

Schultz NM , Shore ND , Chowdhury S , Klotz LH , Concepcion RS , Penson DF , Karsh LI , Yang H , Brown BA , Barlev A , Flanders SC , . BMC urology. 2018 9 6; 18(1). 77
  • NIHMSID: 100968571

ABSTRACT

This analysis estimated the number needed to treat with enzalutamide versus bicalutamide to achieve one additional patient with chemotherapy-naïve metastatic castration-resistant prostate cancer who would obtain clinical benefit regarding progression-free survival, radiographic progression-free survival, or no prostate-specific antigen progression at 1 and 2 years following treatment initiation.

This analysis estimated the number needed to treat with enzalutamide versus bicalutamide to achieve one additional patient with chemotherapy-naïve metastatic castration-resistant prostate cancer who would obtain clinical benefit regarding progression-free survival, radiographic progression-free survival, or no prostate-specific antigen progression at 1 and 2 years following treatment initiation.

Tags: